Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Tarsus Pharmaceuticals Inc (NASDAQ: TARS) was $78.08 for the day, down -2.25% from the previous closing price of $79.88. In other words, the price has decreased by -$2.25 from its previous closing price. On the day, 0.73 million shares were traded. TARS stock price reached its highest trading level at $81.57 during the session, while it also had its lowest trading level at $76.92.
Ratios:
Our analysis of TARS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.25 and its Current Ratio is at 4.29. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $100.
On November 20, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $100.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 02 ’26 when Whitfield Dianne C. sold 15,565 shares for $80.67 per share. The transaction valued at 1,255,684 led to the insider holds 23,393 shares of the business.
Whitfield Dianne C. bought 15,565 shares of TARS for $1,266,680 on Jan 02 ’26. On Dec 24 ’25, another insider, Azamian Bobak R., who serves as the President/CEO and Board Chair of the company, sold 6,000 shares for $82.51 each. As a result, the insider received 495,089 and left with 857,991 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 3314426112 and an Enterprise Value of 2995098112. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.05 while its Price-to-Book (P/B) ratio in mrq is 9.89. Its current Enterprise Value per Revenue stands at 8.181 whereas that against EBITDA is -34.986.
Stock Price History:
The Beta on a monthly basis for TARS is 0.57, which has changed by 0.5160372 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $85.25, while it has fallen to a 52-week low of $38.51. The 50-Day Moving Average of the stock is 1.10%, while the 200-Day Moving Average is calculated to be 37.63%.
Shares Statistics:
TARS traded an average of 555.47K shares per day over the past three months and 836910 shares per day over the past ten days. A total of 42.45M shares are outstanding, with a floating share count of 39.15M. Insiders hold about 7.76% of the company’s shares, while institutions hold 104.84% stake in the company. Shares short for TARS as of 1765756800 were 6807544 with a Short Ratio of 12.26, compared to 1763078400 on 7166734. Therefore, it implies a Short% of Shares Outstanding of 6807544 and a Short% of Float of 16.580000000000002.
Earnings Estimates
The dynamic stock of Tarsus Pharmaceuticals Inc (TARS) is currently attracting attention from 6.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.07, with high estimates of $0.05 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$1.34 and -$1.48 for the fiscal current year, implying an average EPS of -$1.41. EPS for the following year is $1.33, with 5.0 analysts recommending between $2.99 and $0.59.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 7 analysts. It ranges from a high estimate of $145.5M to a low estimate of $142.76M. As of . The current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $66.41MFor the next quarter, 7 analysts are estimating revenue of $148.6M. There is a high estimate of $155M for the next quarter, whereas the lowest estimate is $144.57M.
A total of 8 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $445.2M, while the lowest revenue estimate was $442.45M, resulting in an average revenue estimate of $443.47M. In the same quarter a year ago, actual revenue was $182.95MBased on 7 analysts’ estimates, the company’s revenue will be $679M in the next fiscal year. The high estimate is $776.67M and the low estimate is $604.3M.
